One More Level S.A. (WSE:OML)

Akoya Biosciences Income Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	20.35	22.79	7.12	12.58	0.93
Revenue Growth (YoY)	-10.73%	219.91%	-43.38%	1254.63%	-77.07%
Cost of Revenue	4.81	15.55	0.15	-1.08	0.96
Gross Profit	15.54	7.24	6.98	13.67	-0.03
Selling, General & Admin	5.2	5.18	1.99	5.56	4.6
Other Operating Expenses	-1.47	5.48	5.81	4.44	3.9
Operating Expenses	3.73	10.66	7.8	10.03	8.52
Operating Income	11.81	-3.42	-0.82	3.63	-8.55
Interest Expense	-0.14	-0.1	-0.53	-0.14	-0.41
Interest & Investment Income	0.25	0.11	0.33	0.05	-
Other Non Operating Income (Expenses)	-0.04	-0.59	0.04	0.01	0
EBT Excluding Unusual Items	11.87	-4	-0.98	3.55	-8.95
Gain (Loss) on Sale of Assets	-	-0.04	-	-	-
Asset Writedown	-2.99	-10.96	-	-	-
Pretax Income	8.88	-15	-0.98	3.55	-8.95
Income Tax Expense	1.64	-2.44	0.8	0.14	-
Net Income	7.24	-12.56	-1.78	3.41	-8.95
Net Income to Common	7.24	-12.56	-1.78	3.41	-8.95
Shares Outstanding (Basic)	57	54	54	54	54
Shares Outstanding (Diluted)	57	54	54	54	54
Shares Change (YoY)	5.61%	-	-	-	-
EPS (Basic)	0.13	-0.23	-0.03	0.06	-0.17
EPS (Diluted)	0.13	-0.23	-0.03	0.06	-0.17
Free Cash Flow	1.01	-0.62	4.99	4.65	-3.65
Free Cash Flow Per Share	0.02	-0.01	0.09	0.09	-0.07
Gross Margin	76.35%	31.77%	97.93%	108.60%	-2.91%
Operating Margin	58.03%	-15.00%	-11.57%	28.87%	-920.01%
Profit Margin	35.59%	-55.10%	-25.02%	27.12%	-963.61%
Free Cash Flow Margin	4.94%	-2.71%	70.05%	36.95%	-392.88%
EBITDA	12.05	2.22	4.73	8.06	-4.15
EBITDA Margin	59.23%	9.73%	66.43%	64.03%	-
D&A For EBITDA	0.24	5.64	5.56	4.42	4.4
EBIT	11.81	-3.42	-0.82	3.63	-8.55
EBIT Margin	58.03%	-15.00%	-11.57%	28.87%	-
Effective Tax Rate	18.44%	-	-	3.85%	-
Revenue as Reported	20.35	22.79	7.12	13.76	0.06

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.